[PDF] Top 20 Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
Has 10000 "Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing" found on our website. Below are the top 20 most common "Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing".
Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
... of next generation sequencing (NGS) into cancer genetic interrogation achieved tremendous successes in acquiring cancer genomic information comprehensively and efficiently ...416 ... See full document
9
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring <em>EGFR</em> mutations: a review of the evidence
... to first- and second-generation EGFR/HER-TKI therapy, specific drugs to target this muta- tion are recently under clinical development and may bring a breakthrough for the treatment of NSCLC ... See full document
13
<p>Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer</p>
... in patients with EGFR mutation- positive NSCLC and extend the inhibitory pro fi le to EGFR mutations that were resistant to the fi rst- generation ...the kinase activity of all ... See full document
14
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
... Non-small cell lung cancer (NSCLC) accounts for ap- proximately 85 % of all lung ...NSCLC patients is less than 5 ...Caucasian patients and approximately 30 – 40 % ... See full document
7
Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
... 3rd-generation EGFR-TKIs were recently developed to control lung cancer cells harboring T790M-mediated ...mutant-selective EGFR-TKI WZ4002. We established five WZ4002-resistant ... See full document
11
BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
... Lung cancer is the leading cause of cancer related death in the developed countries and in Latin America, and non–small-cell lung cancer (NSCLC) accounts for most ... See full document
10
Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
... (EGFR) tyrosine kinase inhibitor and has shown a significant clinical benefit in non-small cell lung cancer (NSCLC) patients with EGFR-activating ... See full document
14
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
... The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as ... See full document
10
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non- small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
... 2015, patients from the Sun Yat-Sen University Cancer Center with histologically confirmed stage IIIB/IV NSCLC were included in this ...261 patients (Figure 1) with RECIST progression on EGFR ... See full document
8
Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC
... in patients with non-small-cell lung cancer, such as being less risky and ...in patients clinically resistant to tyrosine kinase ...45 patients ... See full document
6
EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
... receptor tyrosine kinase inhibitors (EGFR-TKIs) have significantly improved outcome of EGFR mutation posi- tive advanced non-small cell lung cancer ... See full document
6
<p>Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors</p>
... limitations. First, this was a retrospective study and patient ’ s backgrounds were ...all patients were Chinese, which may not be representative of other ethnic ...detect EGFR mutations in fresh, ... See full document
10
Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring <em>EGFR</em> exon 20 mutations
... of non-small-cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations carry uncommon ...of first-generation ... See full document
6
<em>EGFR</em> T790M: revealing the secrets of a gatekeeper
... Abstract: Non-small-cell lung cancers that harbor activating mutations in the EGFR gene rep- resent an important molecularly defined subset of lung ...with first- and ... See full document
13
Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
... another cancer type are identified in genes that are potential ...exome sequencing in patients with lung cancer so patients may be advised on the possibility of incidental ... See full document
32
Molecular insights: Suppression of EGFR and AKT activation by a small molecule in non-small cell lung cancer
... growth, cell proliferation, survival, invasion, migration, and EMT ...metastatic cell properties by regulating β-catenin dependent transcription events ...Phosphorylated EGFR activates AKT, which ... See full document
12
<p>Serum Exosomal miR-1290 is a Potential Biomarker for Lung Adenocarcinoma</p>
... LUAD patients and healthy ...evaluated using receiver operating characteristic (ROC) curves and the area under the ROC curve ...performed using the Kaplan-Meier (KM) ...performed using SPSS ... See full document
10
KRAS and the Reality of Personalized Medicine in Non-Small Cell Lung Cancer
... in cell growth and sur- vival (Figure ...in cell prolif- eration, survival, motility and ...against EGFR TKIs. (37,43,44) PIK3CA mutations provide prognostic value for EGFR/KRAS wild-type ... See full document
8
Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer
... DPYD, EGFR, EMSY, EP300, EPHA3, EPHA5, EPHA7, EPHB1, ERBB2, ERBB3, ERBB4, ESR1, FANCA, FANCI, FAT3, FBXW7, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, GATA2, GATA3, GRIN2A, H3F3C, HGF, HIST1H1C, HIST1H3B, HIST1H3G, ... See full document
9
Development of personalized treatments in lung cancer: focusing on the <em>EGFR</em> mutations and beyond
... interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; N/A, not applicable; OS, overall survival; PFS, progression-free survival; TKi, tyrosine kinase inhibitor; iPASS, iReSSA Pan-Asian ... See full document
11
Related subjects